← Back to Screener
TriSalus Life Sciences, Inc. Common Stock (TLSI)
Price$4.49
Favorite Metrics
Price vs S&P 500 (26W)-11.41%
Price vs S&P 500 (4W)10.80%
Market Capitalization$275.75M
All Metrics
Book Value / Share (Quarterly)$0.32
P/TBV (Annual)16.11x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.38
Price vs S&P 500 (YTD)-38.32%
Gross Margin (TTM)84.57%
Net Profit Margin (TTM)-86.88%
EPS (TTM)$-1.07
10-Day Avg Trading Volume0.15M
EPS Excl Extra (TTM)$-1.07
EPS (Annual)$-1.04
ROI (Annual)71.03%
Gross Margin (Annual)84.57%
Cash / Share (Quarterly)$0.41
Revenue Growth QoQ (YoY)59.85%
ROA (Last FY)-111.03%
Revenue Growth TTM (YoY)53.41%
EBITD / Share (TTM)$-0.89
Operating Margin (TTM)-59.68%
Cash Flow / Share (Annual)$-0.38
P/B Ratio32.49x
P/B Ratio (Quarterly)15.66x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)6.39x
Net Interest Coverage (TTM)-6.86x
ROA (TTM)-110.70%
EPS Incl Extra (Annual)$-1.04
Current Ratio (Annual)2.80x
Quick Ratio (Quarterly)2.35x
3-Month Avg Trading Volume0.18M
52-Week Price Return-19.10%
EV / Free Cash Flow (Annual)19.22x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.28
P/S Ratio (Annual)6.11x
Asset Turnover (Annual)1.28x
52-Week High$7.95
EPS Excl Extra (Annual)$-1.04
26-Week Price Return-7.42%
Quick Ratio (Annual)2.35x
13-Week Price Return-23.51%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)2.80x
Enterprise Value$288.358
Asset Turnover (TTM)1.27x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-86.86%
Cash / Share (Annual)$0.41
3-Month Return Std Dev67.85%
Net Income / Employee (TTM)$-0
ROE (Last FY)85.23%
Net Interest Coverage (Annual)-6.86x
EPS Basic Excl Extra (Annual)$-1.04
Receivables Turnover (TTM)7.75x
EV / Free Cash Flow (TTM)46.64x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.07
ROI (TTM)-27.57%
P/S Ratio (TTM)6.11x
Revenue / Share (Annual)$1.19
Tangible BV / Share (Annual)$0.80
Price vs S&P 500 (52W)-48.93%
Year-to-Date Return-35.67%
5-Day Price Return6.15%
EPS Normalized (Annual)$-1.04
ROA (5Y Avg)-89.67%
Net Profit Margin (Annual)-86.88%
Month-to-Date Return12.25%
Cash Flow / Share (TTM)$0.09
EBITD / Share (Annual)$-0.89
Operating Margin (Annual)-59.68%
LT Debt / Equity (Annual)0.20x
LT Debt / Equity (Quarterly)0.20x
EPS Basic Excl Extra (TTM)$-1.07
P/TBV (Quarterly)17.74x
P/B Ratio (Annual)5.02x
Inventory Turnover (TTM)1.96x
Pretax Margin (TTM)-86.86%
Book Value / Share (Annual)$0.80
Price vs S&P 500 (13W)-24.20%
Beta0.57x
Revenue / Share (TTM)$0.96
ROE (TTM)-29.26%
52-Week Low$3.42
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.15
4.15
4.15
4.09
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
TLSITriSalus Life Sciences, Inc. Common Stock | 6.11x | — | 84.57% | -59.68% | $4.49 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
TriSalus Life Sciences develops drug delivery systems and immune-oncology therapeutics for difficult-to-treat hepatocellular and pancreatic cancers. The company commercializes PEDD infusion systems through its TriNav platform with SmartValve technology, while advancing the investigational agent nelitolimod (SD-101) to enhance immune response in liver and pancreatic cancer patients.